Lupin launches Loteprednol Etabonate Ophthalmic Suspension, 0.5 per cent in the US
Loteprednol Etabonate Ophthalmic Suspension (RLD Lotemax) had estimated annual sales of $ 55 million in the US (IQVIA MAT May 2025)
Lupin announced the launch of Loteprednol Etabonate Ophthalmic Suspension, 0.5 per cent, in the United States. Loteprednol Etabonate Ophthalmic Suspension, 0.5 per cent, is bioequivalent to Lotemax Ophthalmic Suspension, 0.5 per cent, of Bausch & Lomb Inc.
Loteprednol Etabonate Ophthalmic Suspension, 0.5 per cent is indicated for the treatment of steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation.
It is also indicated for the treatment of post-operative inflammation following ocular surgery.
Loteprednol Etabonate Ophthalmic Suspension (RLD Lotemax) had estimated annual sales of $ 55 million in the US (IQVIA MAT May 2025).